HS-TREM2 Binding Modulation for Amyloid-Beta Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases like Alzheimer's disease are ineffective in halting or significantly slowing disease progression due to a lack of understanding of molecular mechanisms driving amyloid-β (Aβ) clearance, with existing therapies failing to address faulty Aβ clearance as a central issue in Aβ accumulation.
Innovation Solution
Administering inhibitors of heparan sulfate (HS) biosynthetic enzymes or activators of the Triggering Receptor Expressed on Myeloid Cell-2 (TREM2) to disrupt the HS-TREM2 complex, thereby promoting Aβ clearance and reducing its accumulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used for neurodegenerative diseases, then treatment is provided, but they fail to address faulty Aβ clearance and do not halt or significantly slow disease progression
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism of faulty Aβ clearance by identifying and inhibiting the HS-TREM2 complex interaction. This extraction of the specific pathological mechanism allows for targeted therapeutic intervention that addresses the root cause of Aβ accumulation rather than providing general symptomatic treatment.
Solution Approach 2:
The patent employs small molecule inhibitors that bind to the TREM2 receptor, changing the binding parameters and preventing HS from activating TREM2. This parameter change in receptor-ligand interaction specifically disrupts the pathological Aβ clearance pathway while maintaining other physiological functions.
2Productivity
If Aβ accumulation is not addressed through improved clearance mechanisms, then disease progression continues, but current therapies do not effectively promote Aβ clearance
Solution Approach 1:
The patent uses small molecule inhibitors as intermediary compounds that mediate between the HS ligand and TREM2 receptor. These intermediaries bind to TREM2 and prevent HS from forming the activating complex, thereby interfering with the pathological signal transduction pathway that impairs Aβ clearance.
Solution Approach 2:
The small molecule inhibitors alter the binding parameters of the HS-TREM2 interaction by competing for the same binding site or inducing conformational changes in TREM2. This parameter change prevents the formation of the active complex and restores normal Aβ clearance function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The methods effectively decrease Aβ accumulation by enhancing phagocytosis and degradation, leading to potential therapeutic benefits in treating and preventing neurodegenerative diseases such as Alzheimer's disease.
Implementation Method 1
administering inhibitors of heparan sulfate (HS) biosynthetic enzymes or inhibitors of HS-Triggering Receptor Expressed on Myeloid Cell-2 (HS-TREM2) complex formation
Implementation Method 2
The at least one inhibitor of a HS biosynthetic enzyme comprises an inhibitor of N-deacetylase/N-sulfotransferases-1 (NDST1), an inhibitor of a Exostosin (EXT) glycosyltransferase
Implementation Method 3
The present disclosure provides methods of treating and/or preventing a neurodegenerative disease by administering an agonist/activator of TREM2 activity... increases binding of amyloid-β (Aβ) to the TREM2 and decreases accumulation of Aβ
Data Source
AI summary
The present disclosure relates to methods of treating and/or preventing neurodegenerative diseases by modulating interactions between the heparan sulfate-Triggering Receptor Expressed on Myeloid Cell-2 (HS-TREM2) complex and preventing accumulation of amyloid-β (Aβ).